• Primary reasons to consider an oral JAK inhibitor include debilitating anxiety related to injections, comorbid disease (Alopecia Areata, Vitiligo, Irritable Bowel Disease), dupilumab adverse effects, and dupilumab failures.
  • Patients with alopecia areata consistently demonstrate poorer health-related quality of life than controls, impact similar to atopic dermatitis and psoriasis.
  • Consider using the term alopecia areata for totalis and universalis, as it is a continuum of the same disease.
  • Tofacitinib is approved for Juvenile Idiopathic Arthritis ages 2+
  • SALT score is a measurement of alopecia areata severity. The higher the score the worse the disease on a scale from 0-100.
  • Consider adding oral Minoxidil when treating alopecia areata patients with a JAK inhibitor.